• LAST PRICE
    6.7000
  • TODAY'S CHANGE (%)
    Trending Up0.1200 (1.8237%)
  • Bid / Lots
    6.5600/ 1
  • Ask / Lots
    6.8600/ 2
  • Open / Previous Close
    6.5600 / 6.5800
  • Day Range
    Low 6.4700
    High 6.7100
  • 52 Week Range
    Low 5.8901
    High 30.7500
  • Volume
    21,191
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 6.58
TimeVolumeSLDB
09:32 ET2006.5
09:42 ET2006.51
09:44 ET79716.5001
09:48 ET9006.6
10:06 ET6006.47
11:20 ET1396.47
12:06 ET2346.71
12:50 ET24556.69
01:06 ET2006.65
01:33 ET12046.705
02:09 ET4406.5806
03:21 ET1336.6321
03:26 ET4006.615
03:46 ET1006.635
03:53 ET1006.665
04:00 ET11206.7
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSLDB
Solid Biosciences Inc
49.6M
-0.6x
---
United StatesTCRX
TScan Therapeutics Inc
50.6M
-0.8x
---
United StatesADAG
Adagene Inc
45.5M
-0.6x
---
United StatesCLGN
Collplant Biotechnologies Ltd
59.1M
-3.6x
---
United StatesLPCN
Lipocine Inc
38.7M
9.7x
---
United StatesICCC
ImmuCell Corp
52.3M
-71.1x
---
As of 2022-11-30

Company Information

Solid Biosciences Inc. is a life sciences company that is focused on developing transformative treatments to improve the lives of patients with Duchenne muscular dystrophy (Duchenne). Duchenne is a genetic muscle-wasting disease predominantly affecting boys. SGT-001 and SGT-003 are its gene transfer candidates. SGT-001 and SGT-003 are designed to address the underlying genetic cause of Duchenne by delivering a synthetic transgene that produces dystrophin-like protein that is only expressed in muscles of the body, including cardiac and respiratory muscles. SGT-001 is its lead gene transfer candidate and utilizes an adeno-associated virus (AAV)9 vector. In addition to its gene transfer candidates, it has development programs focusing on platform technologies, including dual gene expression, a technology that allows it to package multiple transgenes into one vector, as well as capsids. It is developing SGT-001 for the treatment of Duchenne through a single intravenous administration.

Contact Information

Headquarters
500 RUTHERFORD AVENUE, 3RD FLOORCHARLESTOWN, MA, United States 02129
Phone
617-337-4680
Fax
302-655-5049

Executives

Chairman of the Board
Ian Smith
President, Chief Executive Officer, Director
Alexander Cumbo
Interim Chief Financial Officer, Treasurer
Stephen Dipalma
Chief Scientific Officer
Carl Morris
Lead Independent Director
Adam Stone

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$49.6M
Revenue (TTM)
$11.2M
Shares Outstanding
7.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.37
EPS
$-11.89
Book Value
$28.30
P/E Ratio
-0.6x
Price/Sales (TTM)
4.4
Price/Cash Flow (TTM)
---
Operating Margin
-804.93%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.